I-Mab To Start Testing Alzheimer's Candidate In Human Trials

by Vandana Singh, Benzinga Editor

July 30, 2021 9:32 AM | 1 min read |

The FDA has signed off I-Mab IMAB Investigational New Drug (IND) application for Protollin, an Alzheimer's candidate.
Brigham and Women's Hospital and Inspirevax granted I-Mab and Nhwa global exclusive licenses to develop, manufacture, and commercialize Protollin.
Inspirevax will manufacture and supply Protollin for preclinical and clinical studies until the recruitment of the first patient in the Phase 1b MAD study.
I-Mab will develop and commercialize Protollin outside of the Greater China territory, while Nhwa will develop and commercialize the drug in mainland China, Hong Kong, Macau, and Taiwan.
Price Action: IMAB shares are down 1.51% at $73.45 during the market session on the last check Friday.
Related content: Benzinga's Full FDA Calendar.

Posted In: Biotech News Health Care FDA General Alzheimer's disease Briefs Investigational New Drug Application

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.